focus -WSS

focus

author：knowledge 2025-09-27 12:48:45 - browse：1225

Sarepta - Cambridge -AP — Kristoffer Tripplaar/Sipa via AP

The Food and Drug Administration granted conditional approval Thursday to the first gene therapy for Duchenne muscular dystrophy. Regulators restricted the treatment to younger patients, with additional data required to broaden its use.

The gene therapy, called Elevydis, is made by Sarepta Therapeutics. The company will charge $3.2 million for the treatment, making it the U.S.’s second most expensive drug, behind a recently approved gene therapy for hemophilia. CEO Doug Ingram said on a conference call the price was below what a recently published company-funded analysis found would be cost-effective.

“The approval of Elevidys is a watershed moment for the treatment of Duchenne. Elevydis is the first and only gene therapy approved for Duchenne, and this approval brings us closer to our goal of bringing forward a treatment that provides the potential to alter the trajectory of this degenerative disease,” Ingram said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Xenotransplantation trials will require adjusting expectations, experts say

hotspot

WSS

U.K. agency declines to back Eli Lilly’s Mounjaro for type 2 diabetes

Biogen nominates mother of director’s child to replace him on board

RaDonda Vaught case: a double standard for nurses, physicians

Option Care buys Amedisys in $3.6 billion home care deal

4th of July breaks record for highest global temperature ever measured

Listen: PBM conflicts, RSV vaccines, & the future of flu season

knowledge

focus

Wikipedia

Guidelines to prevent youth baseball injuries need more muscle

Novo pauses ads for weight loss drug Wegovy amid demand

Cancer drug shortages should be causing more outrage

Novo: Oral version of Ozempic leads to 15% weight loss

Tori Bowie and the unacceptable rates of Black maternal death

A public health expert passes on football's full body collisions for youths

Hepatitis C has a cure — but many Americans still lack access to it

Doctor appointment wait times are getting worse

How one medical school became remarkably diverse

How to fix the rural physician shortage in the U.S.

leisure time

Russia says it foiled Ukrainian drone attack on Moscow as Kyiv's counteroffensive grinds on

Pfizer's Covid pill remains 89% effective in final analysis, company says

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

U.K. agency declines to back Eli Lilly’s Mounjaro for type 2 diabetes

Biden administration plans revamp of organ transplant system

Timeline: Key moments in fight for gay rights

knowledge

knowledge

hotspot

hotspot